Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis

Trial Profile

Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Pharmacokinetics
  • Acronyms GO-KINETIC
  • Most Recent Events

    • 01 Nov 2017 Results assessing association between systemic exposure of Golimumab during induction therapy and endoscopic response, presented at the 25th United European Gastroenterology Week.
    • 10 Jun 2017 Biomarkers information updated
    • 31 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top